LP-003

BIOLOGICAL2 trials

Sponsors

Longbio Pharma

Conditions

Chronic Spontaneous UrticariaSeasonal Allergic Rhinitis

Phase 2

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

CompletedNCT06228560

Longbio PharmaChronic Spontaneous Urticaria

Start: 2024-01-26End: 2025-11-14Updated: 2025-12-12

Phase 3

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

Active, not recruitingNCT07291284

Longbio PharmaSeasonal Allergic Rhinitis

Start: 2024-08-01End: 2026-12-31Updated: 2025-12-26